

HEALTHY HEART

VOLUME-16 | ISSUE-186 | MAY 05, 2025

Price : ₹ 5/-





Honorary Editor :



Dr Milan Chag

MD, DM (Cardiology), DNB (Cardiology)
FACC (Fellow of American College of Cardiology)
Interventional Cardiologist
Heart Failure and Heart Transplant Cardiologist
Structural Heart Disease and TAVI Specialist
Lipidologist and Preventive Cardiologist



HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY:

ALCOHOL SEPTAL ABLATION- A PROVENTHERAPY NOW!

INTRODUCTION AND SALIENT FEATURES:


Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder which is clinically defined by the presence of unexplained left ventricular hypertrophy

(Figure-1 & 2).

Figure-1



Figure-2



- The most common genetic cardiac disease, affecting 1 in 500 individuals.
- It is inherited as an autosomal dominant trait with variable penetrance, most commonly involving sarcomeric protein mutations.
- The disease can be diagnosed in patients of all ages and presents as asymptomatic individual to patients with severe symptoms of exertional dyspnoea or angina and reduced exercise capacity.
- The natural history of the disease may be highly heterogeneous with life expectancy ranging from normal longevity to sudden arrhythmic death (Table 1), often presenting at a young age, or evolution to congestive heart failure atrial fibrillation or stroke.
- Most patients present a characteristic left ventricular morphology with hypertrophy of the basal interventricular septum that is coupled with systolic anterior motion (SAM) of the anterior mitral valve leaflet and leads to

Cardiologists

Dr Tejas V. Patel	(M) +91-89403 05130
Dr Hiren Kevadiya	(M) +91-98254 65205
Dr Gunvant Patel	(M) +91-98240 61266
Dr Keyur Parikh	(M) +91-98250 26999
Dr Milan Chag	(M) +91-98240 22107
Dr Urmil Shah	(M) +91-98250 66939
Dr Hemang Baxi	(M) +91-98250 30111
Dr Anish Chandarana	(M) +91-98250 96922
Dr Ajay Naik	(M) +91-98250 82666
Dr Satya Gupta	(M) +91-99250 45780
Dr Vipul Kapoor	(M) +91-98240 99848
Dr Vineet Sankhla	(M) +91-99250 15056

Cardiothoracic & Vascular Surgeons

Dr Dhiren Shah	(M) +91-98255 75933
Dr Dhaval Naik	(M) +91-90991 11133
Dr Amit Chandan	(M) +91-96990 84097
Dr Nikunj Vyas	(M) +91-73531 65955
Dr Dhyanil Trivedi	(M) +91-99989 67576

Congenital & Structural Heart Disease Specialist

Dr Kashyap Sheth	(M) +91-99246 12288
Dr Milan Chag	(M) +91-98240 22107

Paediatric & Structural Heart Surgeon

Dr Shaunak Shah	(M) +91-98250 44502
-----------------	---------------------

Cardiovascular, Thoracic & Thoracoscopic Surgeon

Dr Pranav Modi	(M) +91-99240 84700
----------------	---------------------

Cardiac Anaesthetists

Dr Niren Bhavsar	(M) +91-9879571917
Dr Hiren Dholakia	(M) +91-9586375818
Dr Chintan Sheth	(M) +91-9173204454

Cardiac Electrophysiologist

Dr Ajay Naik	(M) +91-98250 82666
Dr Hiren Kevadiya	(M) +91-98254 65205




Table-1 Risk Factors For Sudden Cardiac Death

1. Familial sudden death
2. Unexplained syncope
3. Multiple, repetitive NSVT (Holter)
4. Abnormal exercise response
5. Massive LVH Septal thickness > 30 mm
6. Cardiac arrest survivors
7. Documented sustained ventricular tachycardia
8. Cardiac MRI: >15% area with LGE

dynamic left ventricular outflow tract (LVOT) obstruction and mitral regurgitation due to malcoaptation of the mitral leaflets.

- Symptomatic status depends on left ventricular obstruction, diastolic dysfunction and myocardial ischaemia. The existence of significant obstruction at rest or after provocation is associated with symptomatic status and has significant prognostic implications. (Figure-3)

Figure-3




MANAGEMENT:

- In general, treatment of patients with hypertrophic cardiomyopathy aims at relieving symptoms, reducing the risk of sudden death and offering genetic counselling.

- Consequently, treatment of symptomatic patients with obstructive HCM (HOCM) aims at the reduction of the pressure gradient. Medical treatment with β -blockers, disopyramide or verapamil, are first line therapy but some patients remain symptomatic in spite of them. Mavacamten (cardiac myosin inhibitor) is a novel new agent. It has shown significant improvement in symptoms, hemodynamics and cardiac remodeling on short term follow up, Reduction in LVFE due to it needs regular monitoring.
- In drug-refractory patients, alcohol septal ablation (Percutaneous Transluminal Septal Myocardial Ablation-PTSMA) (Figure-4) has emerged as a less invasive

treatment than surgery to reduce LVOT obstruction by creating an infarction limited to the part of the basal septum, involved in the development of LV obstruction (Table-2).

Figure-4



PROCEDURE (PTSMA)

- Under local anesthesia and prophylactic transjugular temporary pacemaker lead insertion, first septal artery is identified and OTW balloon catheter

Table-2 : INDICATIONS FOR SEPTAL REDUCTION (PTSMA) TREATMENT:

CLINICAL INDICATION

- Symptomatic patients
 - ☐ Drug-refractory or severe side effects of drugs
 - ☐ Functional class III and IV or functional class II with objective exercise limitations
 - ☐ Recurrent exercise-induced syncope
- Failure of prior myectomy or pacemaker
- Comorbidity-related increased surgical risk

HAEMODYNAMIC INDICATION

- Intracavitary gradient >30 mmHg at rest and/or
- Provocable gradient >50 mmHg

MORPHOLOGIC INDICATION

- Echocardiography
 - ☐ Subaortic, HCM with SAM-associated gradient
 - ☐ Exclusion of intrinsic mitral valve apparatus disorders
- Coronary angiography
 - ☐ Suitable septal branch



of appropriate size is placed over the guide wire in the artery to occlude it completely. After confirming the target septal tissue by contrast echocardiography, 1 to 3 ml of absolute alcohol (1 ml/ 1 cm of IVS) is injected in target septal artery through central lumen of OTW balloon catheter under continuous ECG and hemodynamic monitoring. At the end, balloon catheter is removed, check angiogram is done and patient is monitored in CCU for 48 hours. (Figure-5, 6)




Figure-5 : Procedure (PTSA)

PATHOPHYSIOLOGICAL EFFECTS OF SEPTAL ABLATION:

- Injection of alcohol during the procedure causes coagulative necrosis of the targeted myocardium and the septal micro vasculature.
- Tissue oedema appears early in this process, while muscle replacement

Figure-6 : Procedure (PTSA)




Figure-7





Figure-8





Figure-9





by scar formation develops only after several days.

- Thinning of the ablated area and scar formation lead to a permanent and significant reduction of the obstruction and the associated mitral regurgitation within the next 6-12 weeks.

CLINICAL RESULTS

- Haemodynamic success with reduction in both resting and provokable gradients is accomplished in $\geq 90\%$ of patients and is associated with significant improvement in symptoms (Figure-7, 8).
- Mean NYHA class decreased from 2.9 to 1.2 and mean CCS class decreased from 1.9 to 0.4 at 1-year follow-up. Exercise capacity also improved on a treadmill. In a cohort of the first 99 consecutive patients treated the overall survival was 98% at 12 years, while 80% of patients

Table-3 : Comparison of Septal Myectomy and Percutaneous Alcohol Septal Ablation

Parameter	Percutaneous Alcohol Septal Ablation	Surgical Myectomy
Invasiveness	Percutaneous access	Sternotomy
Onset of reduction in LVOT	Maximam decrease in gradient instantly,	
Instantaneous		
gradient	And by 6 to 12 week	
Success rate (%)	>90%	>90%
Procedural mortality (%)	<1%	2-10%
Recovery time	2-4 days	2 week
Effect on LVOT gradient	Decreases to <20 mm Hg	Decreases to <10 mm Hg
Postprocedure conduction abnormality (commonest)	Right bundle branch block	Left bundle branch block
Need for permanent pacemaker-all patients (%)	5%	3-10%
Length of follow-up (year)	15-20	30

remained free of severe symptoms, atrial fibrillation, and stroke or ICD implantation. Results of last 12 years are comparable to published literature (Table-3, Figure-9)

CONCLUSIONS

Alcohol septal ablation has emerged in the last 20 years as a less invasive alternative to the standard surgical



treatment of symptomatic patients with HOCM. The accumulated long-term results have shown an ongoing relief of symptoms in the majority of patients. Hospital mortality can be practically eliminated in experienced centers, while the need for permanent pacing has also been reduced with increased experience.

Table-4 : Results

STUDY	NO. OF PATIENTS	AGE (YEARS)	PACEMAKER IN-HOSPITAL (%)	MEN FOLLOW-UP TIME (YEARS)	IN-HOSPITAL MORTALITY (%)	LONG-TERM ALL-CAUSE MORTALITY (%)	REDO PROCEDURES (%)	MYECTOMY (%)	SURVIVAL	SURVIVAL WITHOUT SYMPTOMS
Seggewiss 2007	100	52.7 \pm 15.7	8	4.8 \pm 1.2	1	3			96%@8y	74 %
Welge 2008	347	54 \pm 15	7	4.8 \pm 2.9	1	8	5	3	92%	74 %
Sorajja 2008	138	64 \pm 21	20	2.2 \pm 2.8	1.4	8	4		88%@4y	76.4 %
Kuhn 2008	329	58 \pm 15	17	2.1	1.8	7	13		91.1%	
Fernandes 2008	619	53.9 \pm 15.0	8.2	4.6 \pm 2.5	1	8	14	25	89%@8y	
Kwon 2008	55	63 \pm 13	25.5	8 \pm 1	0	24	5.5	5	76%@10y	
Noseworthy 2009	89			5.0 \pm 2.3		9	10	11	91%	
Ten Cate 2010	91	54 \pm 15	4	5.4 \pm 2.5	2	10	5	5	88%	
Lyne 2010	12	69 \pm 22	0	11.75	0	3	17	0		73%@10y
Chag MC 2023	99	46 \pm 12	3	12.4	0	2	2	0	98 %	80 %



Pioneers in TAVI/TAVR!
Launched in Gujarat in 2015,
We've performed the highest number of
procedures to date, transforming heart care





MARENGO CIMS HOSPITAL WELCOMES NEW SPECIALISTS: EXPERTISE IN SURGICAL ONCOLOGY

AREAS OF EXPERTISE

- Treating various cancers like: **Head & Neck Cancer | Breast Cancer | Thoracic Cancer | Gastrointestinal Cancer | Gynaecological Cancer | Urogenital Cancer**
- Minimal Invasive, Robotic and Complex Cancer Surgeries • Soft Tissue Sarcomas, Skin Malignancy
- Oncoplastic Breast Surgery • Advanced Reconstruction Techniques



Dr Nishant Sanghavi

MBBS, MS, MCh
(Surgical Oncology)
Fellowship in Advanced
Laparoscopic Onco Surgery
Consultant Surgical Oncology
14+ Years of Experience



Dr Urvish Shah

MS, MCh
(Surgical Oncology), FARIS
(Robotic Surgery)
Consultant Surgical Oncology
8+ Years of Experience



Dr Abhishek Jain

MBBS, MS, MCh. (Oncosurgery)
Consultant Minimal Invasive
Thoracic and Breast Onco Surgeon,
Uniportal 3D VATS
Lung Surgery Specialist
14+ Years of Experience



Dr Mohit Korat

MS (General Surgery),
DrNB (Surgical Oncology)
Consultant Surgical Oncology
7+ Years of Experience



Dr Veer R. Shah

MS, MCh (Surgical Oncology)
Oncoplastic Breast Surgeon
7+ Years of Experience



Dr Nikunj Patel

MS, MCh (Surgical Oncology)
Consultant Surgical Oncology
4+ Years of Experience

TEAM OF EXPERTS

- **MEDICAL ONCOLOGY:** Dr Bhavesh Parekh | Dr Yesha Patel • **SURGICAL ONCOLOGY:** Dr Natoo Patel | Dr Ashok Patel | Dr Jayesh Patel | Dr Darshan R. Bhansali | Dr Manish Gandhi | Dr Mahavir Tadaiya | Dr Sarav Shah | Dr Keval Patel | Dr Noopur Patel • **RADIATION ONCOLOGY:** | Dr Devang Bhavsar | Dr Malhar Patel | Dr Maulik Bhensdadia | Dr Prapti Patel Desai • **BONE MARROW TRANSPLANT:** | Dr Kaumil Patel | Dr Ankit Jitani | Dr Hemant Menghani
- **NUCLEAR MEDICINE:** Dr Zeel Soni • **PLASTIC SURGEON:** Dr Vatsal Kothari



HEALTHY HEART

VOLUME-16 | ISSUE-186 | MAY 05, 2025

Healthy Heart Registered under **RNI No. GUJENG/2008/28043**

Published on 5th of every month

Permitted to post at PSO, Ahmedabad-380002 on the 12th to 17th of every month under
Postal Registration No. **GAMC-1725/2024-26** issued by SSP Ahmedabad valid upto 31st December, 2026
Licence to Post Without Prepayment No. **PMG/NG/055/2024-26** valid upto 31st December, 2026

If undelivered Please Return to :


CIMS Hospital,
Nr. Shukan Mall, Off Science City Road,
Sola, Ahmedabad-380060.
Call : 1800 309 9999

Subscribe "Healthy Heart" : Get your "Healthy Heart", the information of the latest medical updates only ₹ 60/- for one year.
To subscribe pay ₹ 60/- in cash or cheque/DD at CIMS Hospital Pvt. Ltd. Nr. Shukan Mall, Off Science City Road, Sola,
Ahmedabad-380060. Phone : +91-79-4805 2823. Cheque/DD should be in the name of : **"CIMS Hospital Pvt. Ltd."**
Please provide your **complete postal address with pincode, phone, mobile and email id** along with your subscription



62,000+

Angioplasty



**One of the Largest
Cardiovascular of India**

Marengo CIMS Hospital,
Off. Science City Rd, Sola, Ahmedabad

Follow us



 **1800 309 9999**

Printed, Published and Edited by Dr. Keyur Parikh on behalf of the CIMS Hospital

Shakti Offset, A-62, Pushraj Industrial Estate, Nutan Mill Road, Behind - Adani CNG Station, Saraspur, Ahmedabad - 380 018
Published from CIMS Hospital, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.